Skip to main content
Clinical Trials/NCT04510740
NCT04510740
Recruiting
N/A

JADE - Clinical Research Platform on Treatment and Outcome in Patients With Hepatocellular or Cholangiocellular Cancer

iOMEDICO AG1 site in 1 country1,000 target enrollmentAugust 9, 2020

Overview

Phase
N/A
Intervention
Not specified
Conditions
Hepatocellular Carcinoma (HCC)
Sponsor
iOMEDICO AG
Enrollment
1000
Locations
1
Primary Endpoint
Course of treatment (treatment reality).
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with Hepatocellular Carcinoma (HCC) or Cholangiocarcinoma (CCC) in Germany.

Detailed Description

JADE is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of HCC or CCC in Germany. The registry will follow patients for up to three years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. Health-related quality of life in patients with HCC / CCC will be evaluated for up to three years.

Registry
clinicaltrials.gov
Start Date
August 9, 2020
End Date
December 2027
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Course of treatment (treatment reality).

Time Frame: 3 years per patient.

Documentation of anamnestic data and therapy sequences.

Secondary Outcomes

  • Progression-free survival.(3 years per patient.)
  • Best Response.(3 years per patient.)
  • Overall survival.(3 years per patient.)
  • Carcinoma Health-related quality of life (Patient-reported outcome, PRO).(3 years per patient.)
  • Health-related quality of life (Patient-reported outcome, PRO).(3 years per patient.)

Study Sites (1)

Loading locations...

Similar Trials